InvestorsHub Logo
icon url

PhoenixRising

09/13/15 7:39 AM

#234822 RE: bidrite #234820

I agree and I believe we still have a respectable amount available from the previous shelf(?) I hope that the excuse of "The BOD and management are holding their cards close to the vest,etc.,etc. and they have their reasons for wanting so many on top of the existing shares." doesn't rear its' head ad nauseum. It's just a lot of shares with no explanation,IMO. The timing of proposed AS increase with the look-ins statement is just a little strange...TO ME. It won't matter how we vote because it will pass. Never a dull moment in PPHM-land,IMO. carpe diem PR
icon url

war0001

09/13/15 9:51 AM

#234835 RE: bidrite #234820

Were we not all put into this bad position of voting on additional shares because of the bad decision of management to limit ECOG performance status for SUNRISE to 0-1? If they had extended this range to 0-2 do you not believe that First-look-in would have not already occurred? Now we wait until 1Q next year.

Was the lack of faith in Bavi warranted? Results would have probably been public, partnerships formed, etc.



icon url

Protector

09/13/15 10:41 AM

#234841 RE: bidrite #234820

bidrite, a very big effort is made to make everyone believe we are far from the target (some have projected Bavi in 2018) and an even bigger effort is made to make everyone believe PPHM PPS will not appreciate until approval by the FDA.

We have however seen in

A) 2012 with the 2nd ln NSCL interim results that this is not so, the PPS anticipates. This time the market will know PPHM will not lightly announce interim results which will make them the more valuable. The payment from CSM (600K$) is not much but it confirms THEY F..ed. UP our trial and that is what needed to be out there.

B) That if this kind of collaborations/partnerships such as with Memorial Sloan Kettering, AstraZeneca keep coming the marked is going to start looking completely different on PPHM.

C) With Avid II commercialisation of Bavi will be sped up compared to a company that needs to outsource its production to 3rd parties.

D) With the fast track a big part of the BLA is already made and discussed with the FDA. rest assured that Garnick will milk the Fast Trac's possibilities to the last drop.

E) And we haven't either considered an early stop at the look-ins or the granting of a priority Review.

So events are much closer then we think and the 175Mil$ shelf will very probably MOSTLY serve for OTHER things then the ongoing SUNRISE.



icon url

tarvacin

09/13/15 10:45 AM

#234842 RE: bidrite #234820

Bingo, if successful shares would not be needed.

What does this tell you?

Not rocket surgery.